Answers are grounded in this paper and cite their sources.
Animal experiments demonstrate magnesium sulfate's role in reducing seizure severity in COVID-19, suggesting its therapeutic potential.
Nikethamide, a respiratory stimulant, is used to treat hypoxemia caused by coronavirus disease 2019 (COVID-19), but it carries a risk of convulsions. Magnesium sulfate (MgSO4), a seizure inhibitor, might serve as a rescue agent against nikethamide-induced seizures. To investigate the therapeutic effect of MgSO4 on nikethamide -induced seizures in COVID-19 patients through animal experiments, providing experimental support for the clinical application of MgSO4 in preventing and treating seizures caused by nikethamide. Forty mice were randomly divided into four groups: (1) Physiological saline; (2) Low-dose MgSO4 (50 mg/kg); (3) Medium-dose MgSO4 (100 mg/kg); and (4) High-dose MgSO4 (200 mg/kg). After 15 minutes of intraperitoneal injection of different doses of MgSO4 or an equal volume of physiological saline, the mice were injected with nikethamide (250 mg/kg). Compared to the normal saline group, all doses of MgSO4 significantly prolonged the seizure latency and reduced the severity of convulsions. However, they also extended the duration of seizures and correspondingly increased survival time (P < 0.05). The incidence of seizures and mortality rate in the MgSO4-treated groups were significantly lower than those in the normal saline group (P < 0.05). MgSO4 can prevent and treat seizures caused by nikethamide in mice. This finding has implications for the application of MgSO4 in treating and preventing seizures caused by nikethamide in COVID-19 treatment.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: